Reply from faron pharmaceuticals19 Feb 2020 17:27
I asked why they didnt issue RNS regarding news,
Dear Christopher,
Thank you for your email concerning the CEO interview this week.
We respond to shareholder enquiries on behalf of Faron Senior Management.
You will probably have seen that the Company provided the market with an update on Traumakine and the new trial protocol submitted to the US Food and Drug Administration, on 6 February. The CEO interview this week did not disclose further market sensitive information concerning Traumakine, and so did not warrant a RNS announcement.
Should there be material new market sensitive information , it will be announced via RNS in line with regulatory requirements.
Kind regards,
Carina